Effect of the fluoroquinolone antibacterial agent DX-619 on the apparent formation and renal clearances of 6β-hydroxycortisol, an endogenous probe for CYP3A4 inhibition, in healthy subjects

Pharmaceutical Research

Volumn 30, Issue 2, 2013, Pages 447-457

  Imamura, Yuichiro ^a   Murayama, Nobuyuki ^a   Okudaira, Noriko ^a   Kurihara, Atsushi ^a   Inoue, Katsuhisa ^b   Yuasa, Hiroaki ^b   Izumi, Takashi ^a   Kusuhara, Hiroyuki ^c   Sugiyama, Yuichi ^d  

^a DAIICHI SANKYO CO   (Japan)

^b NAGOYA CITY UNIVERSITY   (Japan)

^c UNIVERSITY OF TOKYO   (Japan)

^d INST OF PHYS AND CHEMICAL RESEARCH   (Japan)

Author keywords

CYP3A4; drug drug interaction; mechanism based inhibition (MBI); renal drug transporter; tubular secretion

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE 1; 11BETA HYDROXYSTEROID DEHYDROGENASE 2; 6BETA HYDROXYHYDROCORTISONE; 7 [3 (1 AMINOCYCLOPROPYL) 1 PYRROLIDINYL] 1 (2 FLUOROCYCLOPROPYL) 1,4 DIHYDRO 8 METHOXY 4 OXO 3 QUINOLINECARBOXYLIC ACID; CELL PROTEIN; CYTOCHROME P450 3A4; HYDROCORTISONE; MIDAZOLAM; PLACEBO; PROTEIN MATE1; PROTEIN MATE2 K; PROTEIN OAT1; PROTEIN OAT3; UNCLASSIFIED DRUG;

AREA UNDER THE CURVE; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG STRUCTURE; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; HYDROCORTISONE BLOOD LEVEL; HYDROXYLATION; IN VITRO STUDY; IN VIVO STUDY; INHIBITION KINETICS; KIDNEY CLEARANCE; LIVER MICROSOME; MALE; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SINGLE DRUG DOSE; URINARY EXCRETION;

ANTI-BACTERIAL AGENTS; CYTOCHROME P-450 CYP3A; FEMALE; HEK293 CELLS; HUMANS; HYDROCORTISONE; MALE; MICROSOMES, LIVER; ORGANIC ANION TRANSPORT PROTEIN 1; ORGANIC ANION TRANSPORTERS, SODIUM-INDEPENDENT; ORGANIC CATION TRANSPORT PROTEINS; PYRROLIDINES; QUINOLONES;

EID: 84873424011     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-012-0890-6     Document Type: Article

References (28)

1. Honig PK, Wortham DC, Zamani K, Conner DP, Mullin JC, Cantilena LR. Terfenadine-ketoconazole interaction. Pharmacokinetic and electrocardiographic consequences. JAMA. 1993;269:1513-8.
2. Abel SM, Maggs JL, Back DJ, Park BK. Cortisol metabolism by human liver in vitro-I. Metabolite identification and inter-individual variability. J Steroid Biochem Mol Biol. 1992;43:713-9.
3. Peng CC, Templeton I, Thummel KE, Davis C, Kunze KL, Isoherranen N. Evaluation of 6beta-Hydroxycortisol, 6beta-Hydroxycortisone, and a Combination of the Two as Endogenous Probes for Inhibition of CYP3A4 In Vivo. Clin Pharmacol Ther. 2011;89:888-95.
4. de Wildt SN, Kearns GL, Leeder JS, van den Anker JN. Cytochrome P450 3A: ontogeny and drug disposition. Clin Pharmacokinet. 1999;37:485-505.
5. Saenger P. 6 beta-hydroxycortisol in random urine samples as an indicator of enzyme induction. Clin Pharmacol Ther. 1983;34:818-21.
6. Bienvenu T, Rey E, Pons G, d'Athis P, Olive G. A simple non-invasive procedure for the investigation of cytochrome P-450 IIIA dependent enzymes in humans. Int J Clin Pharmacol Ther Toxicol. 1991;29:441-5.
7. Furuta T, Suzuki A, Mori C, Shibasaki H, Yokokawa A, Kasuya Y. Evidence for the validity of cortisol 6 beta-hydroxylation clearance as a new index for in vivo cytochrome P450 3A phenotyping in humans. Drug Metab Dispos. 2003;31:1283-7.
8. Ushiama H, Echizen H, Nachi S, Ohnishi A. Dose-dependent inhibition of CYP3A activity by clarithromycin during Helicobacter pylori eradication therapy assessed by changes in plasma lansoprazole levels and partial cortisol clearance to 6beta-hydroxycortisol. Clin Pharmacol Ther. 2002;72:33-43.
9. Fujikawa K, Chiba M, Tanaka M, Sato K. In vitro antibacterial activity of DX-619, a novel des-fluoro(6) quinolone. Antimicrob Agents Chemother. 2005;49:3040-5.
10. Asif AR, Steffgen J, Metten M, Grunewald RW, Muller GA, Bahn A, et al. Presence of organic anion transporters 3 (OAT3) and 4 (OAT4) in human adrenocortical cells. Pflugers Arch. 2005;450:88-95.
11. Ueda K, Okamura N, Hirai M, Tanigawara Y, Saeki T, Kioka N, et al. Human P-glycoprotein transports cortisol, aldosterone, and dexamethasone, but not progesterone. J Biol Chem. 1992;267:24248-52.
12. Imamura Y, Murayama N, Okudaira N, Kurihara A, Okazaki O, Izumi T, et al. Prediction of fluoroquinolone-induced elevation in serum creatinine levels: a case of drug-endogenous substance interaction involving the inhibition of renal secretion. Clin Pharmacol Ther. 2011;89:81-8.
13. Watanabe A, Nakamura K, Okudaira N, Okazaki O, Sudo K. Risk assessment for drug-drug interaction caused by metabolism-based inhibition of CYP3A using automated in vitro assay systems and its application in the early drug discovery process. Drug Metab Dispos. 2007;35:1232-8.
14. Kanamitsu S, Ito K, Green CE, Tyson CA, Shimada N, Sugiyama Y. Prediction of in vivo interaction between triazolam and erythromycin based on in vitro studies using human liver microsomes and recombinant human CYP3A4. Pharm Res. 2000;17:419-26.
15. Lai AA, Levy RH, Cutler RE. Time-course of interaction between carbamazepine and clonazepam in normal man. Clin Pharmacol Ther. 1978;24:316-23.
16. Fromm MF, Busse D, Kroemer HK, Eichelbaum M. Differential induction of prehepatic and hepatic metabolism of verapamil by rifampin. Hepatology. 1996;24:796-801.
17. Hsu A, Granneman GR, Witt G, Locke C, Denissen J, Molla A, et al. Multiple-dose pharmacokinetics of ritonavir in human immunodeficiency virus-infected subjects. Antimicrob Agents Chemother. 1997;41:898-905.
18. Enomoto A, Takeda M, Taki K, Takayama F, Noshiro R, Niwa T, et al. Interactions of human organic anion as well as cation transporters with indoxyl sulfate. Eur J Pharmacol. 2003;466:13-20.
19. Matsushima S, Maeda K, Inoue K, Ohta KY, Yuasa H, Kondo T, et al. The inhibition of human multidrug and toxin extrusion 1 is involved in the drug-drug interaction caused by cimetidine. Drug Metab Dispos. 2009;37:555-9.
20. Ohta KY, Imamura Y, Okudaira N, Atsumi R, Inoue K, Yuasa H. Functional characterization of multidrug and toxin extrusion protein 1 as a facilitative transporter for fluoroquinolones. J Pharmacol Exp Ther. 2009;328:628-34.
21. Smith AJ, Mayer U, Schinkel AH, Borst P. Availability of PSC833, a substrate and inhibitor of P-glycoproteins, in various concentrations of serum. J Natl Cancer Inst. 1998;90:1161-6.
22. Kodaira H, Kusuhara H, Ushiki J, Fuse E, Sugiyama Y. Kinetic analysis of the cooperation of P-glycoprotein (P-gp/Abcb1) and breast cancer resistance protein (Bcrp/Abcg2) in limiting the brain and testis penetration of erlotinib, flavopiridol, and mitoxantrone. J Pharmacol Exp Ther. 2010;333:788-96.
23. Waters NJ, Jones R, Williams G, Sohal B. Validation of a rapid equilibrium dialysis approach for the measurement of plasma protein binding. J Pharm Sci. 2008;97:4586-95.
24. Cho YS, Kim CH, Cheon HG. Cell-based assay for screening 11beta-hydroxysteroid dehydrogenase 1 inhibitors. Anal Biochem. 2009;392:110-6.
25. Brown RW, Chapman KE, Kotelevtsev Y, Yau JL, Lindsay RS, Brett L, et al. Cloning and production of antisera to human placental 11 beta-hydroxysteroid dehydrogenase type 2. Biochem J. 1996;313(Pt 3):1007-17.
26. Hasegawa M, Kusuhara H, Endou H, Sugiyama Y. Contribution of organic anion transporters to the renal uptake of anionic compounds and nucleoside derivatives in rat. J Pharmacol Exp Ther. 2003;305:1087-97.
27. Nozaki Y, Kusuhara H, Kondo T, Hasegawa M, Shiroyanagi Y, Nakazawa H, et al. Characterization of the uptake of organic anion transporter (OAT) 1 and OAT3 substrates by human kidney slices. J Pharmacol Exp Ther. 2007;321:362-9.
28. Otsuka M, Matsumoto T, Morimoto R, Arioka S, Omote H, Moriyama Y. A human transporter protein that mediates the final excretion step for toxic organic cations. Proc Natl Acad Sci U S A. 2005;102:17923-8.